APGE
Price:
$35.5
Market Cap:
$2.11B
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Industry
Biotechnology
IPO Date
2023-07-14
Stock Exchange
NASDAQ
Ticker
APGE
According to Apogee Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -21.87%. This represents a change of 304.48% compared to the average of -5.41% of the last 4 quarters.
The mean historical ROE of Apogee Therapeutics, Inc. over the last ten years is 25.96%. The current -21.87% ROE has changed -184.23% with respect to the historical average. Over the past ten years (40 quarters), APGE's ROE was at its highest in in the December 2022 quarter at 35.21%. The ROE was at its lowest in in the December 2023 quarter at -8.35%.
Average
25.96%
Median
0%
Minimum
-22.11%
Maximum
100.00%
Discovering the peaks and valleys of Apogee Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 100.00%
Minimum Annual Increase = -122.11%
Minimum Annual ROE = -22.11%
Year | ROE | Change |
---|---|---|
2024 | 0% | -100.00% |
2023 | -22.11% | -122.11% |
The current ROE of Apogee Therapeutics, Inc. (APGE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
25.96%
5-year avg
25.96%
10-year avg
25.96%
Apogee Therapeutics, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apogee Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Apogee Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Apogee Therapeutics, Inc.'s ROE?
How is the ROE calculated for Apogee Therapeutics, Inc. (APGE)?
What is the highest ROE for Apogee Therapeutics, Inc. (APGE)?
What is the 3-year average ROE for Apogee Therapeutics, Inc. (APGE)?
What is the 5-year average ROE for Apogee Therapeutics, Inc. (APGE)?
How does the current ROE for Apogee Therapeutics, Inc. (APGE) compare to its historical average?